Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EXAS logo EXAS
Upturn stock ratingUpturn stock rating
EXAS logo

EXACT Sciences Corporation (EXAS)

Upturn stock ratingUpturn stock rating
$53.65
Last Close (24-hour delay)
Profit since last BUY-4.05%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: EXAS (1-star) is a SELL. SELL since 4 days. Profits (-4.05%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

26 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $68.81

Year Target Price $68.81

Analyst’s Price TargetsFor last 52 week
$68.81Target price
Low$39.97
Current$53.65
high$72.83

Analysis of Past Performance

Type Stock
Historic Profit -24.42%
Avg. Invested days 39
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 10.12B USD
Price to earnings Ratio -
1Y Target Price 68.46
Price to earnings Ratio -
1Y Target Price 68.46
Volume (30-day avg) -
Beta 0.98
52 Weeks Range 39.97 - 72.83
Updated Date 06/29/2025
52 Weeks Range 39.97 - 72.83
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.53

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -36.06%
Operating Margin (TTM) -11.53%

Management Effectiveness

Return on Assets (TTM) -1.83%
Return on Equity (TTM) -36.89%

Valuation

Trailing PE -
Forward PE 2500
Enterprise Value 11859292909
Price to Sales(TTM) 3.58
Enterprise Value 11859292909
Price to Sales(TTM) 3.58
Enterprise Value to Revenue 4.19
Enterprise Value to EBITDA 215.11
Shares Outstanding 188638000
Shares Floating 186787137
Shares Outstanding 188638000
Shares Floating 186787137
Percent Insiders 0.92
Percent Institutions 98.57

Analyst Ratings

Rating 4.54
Target Price 68.81
Buy 6
Strong Buy 17
Buy 6
Strong Buy 17
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

EXACT Sciences Corporation

stock logo

Company Overview

overview logo History and Background

EXACT Sciences Corporation was founded in 1995. Initially focused on DNA-based diagnostics for cancer, it gained prominence with the development and commercialization of Cologuard, a noninvasive colon cancer screening test. The company has expanded through organic growth and acquisitions to offer a broader range of cancer diagnostics.

business area logo Core Business Areas

  • Screening: Focuses on early detection of colorectal cancer through Cologuard and related services.
  • Precision Oncology: Provides genomic testing services to guide cancer treatment decisions, including Oncotype DX.
  • COVID-19 Testing: Offered COVID-19 testing services during the pandemic; this segment is decreasing in significance.

leadership logo Leadership and Structure

Kevin Conroy is the Chairman and CEO. The company has a standard corporate structure with departments for R&D, marketing, sales, operations, and finance. A Board of Directors provides oversight and strategic guidance.

Top Products and Market Share

overview logo Key Offerings

  • Cologuard: A noninvasive stool DNA screening test for colorectal cancer. It is the company's primary revenue driver. Exact Sciences estimates it has ~40% market share of the non-invasive colorectal cancer screening market. Competitors include colonoscopies, fecal immunochemical tests (FIT), and other stool DNA tests (e.g., from Freenome, Guardant Health).
  • Oncotype DX: A suite of genomic tests that analyze tumor samples to predict the likelihood of cancer recurrence and response to chemotherapy. Competitors include Genomic Health, Foundation Medicine and other diagnostic testing companies.

Market Dynamics

industry overview logo Industry Overview

The cancer diagnostics market is growing rapidly, driven by increasing cancer incidence, advancements in genomic technologies, and a focus on early detection and personalized medicine. Key trends include liquid biopsies, multi-cancer early detection (MCED) tests, and the integration of AI and machine learning.

Positioning

EXACT Sciences is a leading player in the noninvasive colorectal cancer screening market with Cologuard. It also holds a strong position in the genomic testing market with Oncotype DX. The company is focused on expanding its product portfolio and market reach through strategic acquisitions and partnerships.

Total Addressable Market (TAM)

The TAM for cancer diagnostics is estimated to be tens of billions of dollars globally. EXACT Sciences is targeting various segments of this market, including colorectal cancer screening, other gastrointestinal cancers, and multi-cancer early detection (MCED). Their TAM includes both screening markets and precision oncology.

Upturn SWOT Analysis

Strengths

  • Strong brand recognition with Cologuard
  • Established market presence in colorectal cancer screening
  • Proprietary technology and intellectual property
  • Experienced management team
  • Direct-to-consumer marketing capabilities

Weaknesses

  • Reliance on a single primary product (Cologuard)
  • High marketing and sales expenses
  • Reimbursement risks from payers
  • Competition from established screening methods like colonoscopy
  • Profitability concerns

Opportunities

  • Expansion into new cancer screening markets (e.g., liver, esophageal)
  • Development of multi-cancer early detection (MCED) tests
  • Strategic partnerships with healthcare providers and payers
  • International expansion
  • Technological advancements in liquid biopsies and genomic testing

Threats

  • Increased competition from other diagnostic companies
  • Changes in healthcare regulations and reimbursement policies
  • Adverse clinical trial results
  • Economic downturn affecting healthcare spending
  • Technological disruption from new diagnostic methods

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • DGX
  • LH
  • FGEN

Competitive Landscape

EXACT Sciences has a strong position in the noninvasive colorectal cancer screening market, but faces increasing competition from established players and new entrants. The company's success depends on its ability to innovate, expand its product portfolio, and effectively market its products.

Major Acquisitions

PreventionGenetics

  • Year: 2021
  • Acquisition Price (USD millions): 190
  • Strategic Rationale: Expanded the company's genetic testing portfolio and capabilities.

Thrive Earlier Detection Corp.

  • Year: 2021
  • Acquisition Price (USD millions): 2150
  • Strategic Rationale: To accelerate the development and commercialization of a multi-cancer early detection (MCED) test.

Growth Trajectory and Initiatives

Historical Growth: EXACT Sciences has experienced significant revenue growth driven by increasing Cologuard adoption and acquisitions. However, profitability remains a challenge.

Future Projections: Analyst estimates for future growth vary depending on factors such as market penetration, competition, and regulatory approvals. Analysts on average have a BUY rating.

Recent Initiatives: Recent initiatives include expanding the Cologuard sales force, investing in R&D for new diagnostic tests, and pursuing strategic acquisitions and partnerships.

Summary

EXACT Sciences is a leading diagnostics company, particularly known for its Cologuard test. The company has grown significantly through innovation and acquisitions, but profitability remains a challenge. While Cologuard dominates the noninvasive colorectal cancer screening market, competition is increasing. Future success hinges on expanding its product portfolio and managing costs effectively.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Investor Relations Materials
  • Third-party Market Research Reports
  • Analyst Reports
  • Company Press Releases

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About EXACT Sciences Corporation

Exchange NASDAQ
Headquaters Madison, WI, United States
IPO Launch date 2001-02-01
Chairman of the Board & CEO Mr. Kevin T. Conroy J.D.
Sector Healthcare
Industry Diagnostics & Research
Full time employees 6900
Full time employees 6900

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.